GLP-1 performance enhancing drugs: Is Serena Williams’s comeback a doping breach?

GLP-1 performance enhancing drugs: medical breakthrough or doping aid?

When Serena Williams returned to the court, a new weight‑loss drug—semaglutide, a GLP‑1 analogue—was cited as easing her recovery. The question echoing through sports medicine circles is whether GLP-1 performance enhancing drugs constitute a violation of anti‑doping rules. Experts split: some argue the drug’s primary function is metabolic, not ergogenic; others point to its ability to accelerate fat loss and improve endurance.

“The line between therapy and advantage is blurry,” says a World Anti‑Doping Agency analyst.

Data from the U.S. health‑care market show a ↑ 10% surge in GLP‑1 prescriptions since 2022, while reported doping cases linked to weight‑loss agents have dipped ↓ 2%. The disparity fuels a policy tug‑of‑war.

Regulators in Europe are drafting guidance that could label off‑label GLP‑1 use as a prohibited method, whereas the U.S. Reuters notes the FDA has not classified these drugs as performance enhancers. Meanwhile, the tennis world watches anxiously, awaiting a definitive ruling.

Dispatch from Declan Cross (Interim Market Researcher).
(Note: Declan Cross is covering this desk while Elena Rostova is on sick leave.)